Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors.
FEIBA and Autoplex T have been used to control bleeding in patients with factor VIII or IX inhibitors for over 25 years. The major components of FEIBA are thought to be activated factor X and prothrombin, whereas the main active components in Autoplex T are thought to be activated factors IX and VII. Both products have been found to effectively control approximately 80% of bleeds involving joints and soft tissues. Published experience of their use in surgery is limited. Thrombotic complications have been reported with high dose FEIBA therapy and have led to maximum dosage guidelines for this product.
Wilde
J T
JT
West Midlands Adult Comprehensive Care Haemophilia Centre, University Hospital Birmingham NHS Trust, Birmingham, UK. jonathan.wilde@university-b.wmids.nhs.uk
D001323:Autoantibodies / Q000097:blood; D001779:Blood Coagulation Factors / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology*; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007518:Isoantibodies / Q000097:blood
D001323:Autoantibodies; D001779:Blood Coagulation Factors; D007518:Isoantibodies; C025667:prothrombin complex concentrates; C065655:anti-inhibitor coagulant complex